e-CONNECT

Interview with the Expert:
Prof. Rury Holman – Insights from the EXSCEL Trial

Diabetes
5 months ago, OP Editor

The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) is a trial that assessed the long-term cardiovascular safety and efficacy of exenatide, administered once-weekly, in patients with type 2 diabetes who had a wide range of cardiovascular risk. In this video, the principal investigator of EXSCEL, Professor Rury Holman (Director of the Diabetes Trials Unit, University of Oxford, United Kingdom) shared his insights into the results of the trial.

This is an independent editorial material, published and distributed through unrestricted educational support from the pharmaceutical community, for the purpose of continuing medical education only.

Menu Section